Sugammadex Adroiq

What Is Sugammadex Adroiq and What Is It Used For?

Sugammadex Adroiq contains the active substance sugammadex, a modified gamma-cyclodextrin that acts as a selective relaxant binding agent (SRBA). Unlike traditional reversal agents that work by inhibiting the enzyme acetylcholinesterase, sugammadex has a unique molecular mechanism: it directly encapsulates (wraps around) the neuromuscular blocking agents rocuronium bromide and vecuronium bromide, forming a tight, water-soluble, inactive complex. This complex is then excreted by the kidneys, effectively removing the muscle relaxant from the body within hours.

During many surgical procedures, general anaesthesia includes neuromuscular blocking agents (NMBAs) that cause complete skeletal muscle relaxation. This paralysis makes it easier for the surgeon to operate, particularly during abdominal, thoracic, cardiothoracic, and orthopaedic procedures, and it facilitates safe endotracheal intubation and mechanical ventilation. However, because these drugs also paralyse the respiratory muscles and diaphragm, patients require mechanical ventilation (artificial breathing support) throughout the operation and often into the immediate post-operative period until spontaneous respiration returns.

Sugammadex Adroiq is used to speed up the recovery of muscle function after surgery so that patients can resume spontaneous breathing, protective airway reflexes, and full muscle strength more quickly. By selectively binding to rocuronium or vecuronium molecules in the bloodstream, sugammadex rapidly reduces the free concentration of these blocking agents at the neuromuscular junction. This results in a much faster and more predictable reversal of paralysis compared to the conventional approach of either waiting for the drug to wear off naturally or using older reversal agents such as neostigmine combined with glycopyrrolate or atropine.

The drug is approved for use in adults when either rocuronium or vecuronium has been used as the neuromuscular blocking agent. For the paediatric population (children aged 2 to 17 years), sugammadex is recommended only for routine reversal of rocuronium-induced blockade. In some jurisdictions, use has been extended to neonates and infants under specialist supervision, though data in these youngest groups remain more limited. Sugammadex was first approved by the European Medicines Agency (EMA) in 2008 and subsequently by the U.S. Food and Drug Administration (FDA) in 2015, and it has since become a standard component of modern perioperative care worldwide, with generic versions such as Sugammadex Adroiq broadening access following patent expiry.

About the Generic: Sugammadex Adroiq

Sugammadex Adroiq is marketed as a generic medicinal product containing sugammadex sodium at 100 mg/ml. As a generic, it has been approved on the basis of demonstrated pharmaceutical equivalence and bioequivalence with the reference product. This means that it contains the same active substance, at the same strength, in the same dosage form, and delivers the same amount of active drug to the systemic circulation. Healthcare professionals can therefore expect the clinical performance of Sugammadex Adroiq to be identical to that of the originator sugammadex in terms of speed of reversal, dose ranges, safety profile, and drug interaction potential.

Clinical Context in Anaesthesia Practice

Incomplete reversal of neuromuscular blockade — known as residual neuromuscular blockade or residual curarisation — is a well-documented risk of modern anaesthesia. Even minor residual blockade (a train-of-four ratio below 0.9 at the adductor pollicis muscle) is associated with an increased risk of upper airway obstruction, impaired hypoxic ventilatory drive, aspiration, atelectasis, and postoperative pulmonary complications. By providing rapid, reliable, and monitorable reversal, sugammadex has meaningfully reduced the incidence of residual blockade in routine practice. The widespread availability of generic formulations such as Sugammadex Adroiq supports these clinical gains while helping health systems manage costs.

What Should You Know Before Receiving Sugammadex Adroiq?

Because Sugammadex Adroiq is a hospital-administered medicine given during anaesthesia, the anaesthesiologist will conduct a full pre-operative assessment before deciding whether it is suitable. Patients and caregivers should, however, ensure that specific medical conditions and medications are disclosed during the anaesthetic consultation, as these may influence dosing, monitoring, or the choice of reversal strategy.

Contraindications

Sugammadex Adroiq must not be given to anyone who has a known allergy (hypersensitivity) to sugammadex sodium or any of the excipients in the formulation. If you have previously experienced an allergic reaction to sugammadex — even if it was considered mild — it is essential to inform your anaesthesiologist before any future surgical procedure, as re-exposure could trigger a more severe reaction. Hypersensitivity reactions to sugammadex, including anaphylaxis, have been documented in both clinical trials and post-marketing surveillance across multiple sugammadex products.

There are no other absolute contraindications; however, the drug is not recommended (a strong relative contraindication) in patients with severe renal impairment, including those requiring dialysis, as detailed below.

Warnings and Precautions

Before receiving Sugammadex Adroiq, speak with your anaesthesiologist if any of the following conditions apply to you:

• Kidney disease: Sugammadex is excreted almost entirely through the kidneys. Sugammadex Adroiq is not recommended for patients with severe renal impairment (creatinine clearance below 30 ml/min), including those on dialysis. Patients with mild to moderate kidney problems may still receive it, but closer monitoring may be appropriate and re-dosing intervals for rocuronium or vecuronium should be extended.
• Liver disease: Although sugammadex is not metabolised by the liver or excreted in bile, patients with severe hepatic impairment should be treated with particular caution. If liver disease is accompanied by coagulopathy, the bleeding-risk considerations below apply in addition.
• Fluid retention (oedema) and cardiovascular disease: Conditions associated with prolonged circulation time, such as peripheral oedema, congestive heart failure, or advanced cardiovascular disease, may delay the time to full recovery after Sugammadex Adroiq administration.
• Bleeding disorders or anticoagulant therapy: Sugammadex can cause a transient, limited prolongation of the activated partial thromboplastin time (aPTT) and prothrombin time (PT/INR). These effects are generally short-lived (under 30 minutes) and not clinically significant for most patients. However, an increased risk of bleeding cannot be excluded in patients with hereditary coagulation factor deficiencies, existing coagulopathies, those taking coumarin derivatives with an INR above 3.5, or those receiving the 16 mg/kg dose.
• Severe bradycardia and cardiac history: Isolated cases of marked bradycardia and cardiac arrest have been reported within minutes of administration. Patients should be closely monitored for haemodynamic changes during and after administration, and treatment with an anticholinergic (e.g. atropine) should be readily available.
• Morbid obesity: For patients with a body mass index (BMI) of 40 kg/m² or higher, doses are calculated using actual body weight, which may result in larger total doses.

Pregnancy and Breastfeeding

There are no adequate data on the use of sugammadex in pregnant women. Animal studies have not shown direct or indirect harmful effects on pregnancy, embryo-foetal development, parturition, or postnatal development. Sugammadex Adroiq should be used during pregnancy only when the clinical benefit justifies the potential risk, and the decision should be made in consultation with the treating anaesthesiologist. Where possible, elective procedures requiring neuromuscular blockade should be deferred until after pregnancy.

It is unknown whether sugammadex is excreted in human breast milk. Animal studies have shown excretion into breast milk, but oral absorption of cyclodextrins is generally low, and no effect on a breastfed infant is expected after a single intravenous dose. A decision should be made by the treating physician, weighing the benefit of breastfeeding for the child against the benefit of surgical treatment for the mother. Pumping and discarding milk for a short period after administration is not routinely required, but individual circumstances should be discussed.

Effects on the Ability to Drive and Use Machines

Because Sugammadex Adroiq is given in the context of general anaesthesia, driving and operating machinery are prohibited for at least 24 hours after the operation, or longer depending on the procedure and institutional discharge criteria. Sugammadex itself has no direct sedating effect, but the residual effects of anaesthetic agents and opioid analgesics can impair cognitive and psychomotor performance.

Sodium Content

Sugammadex Adroiq contains up to 9.7 mg of sodium per millilitre, corresponding to approximately 0.5% of the WHO recommended maximum daily dietary intake of 2 grams of sodium for adults. This is generally clinically insignificant for a single perioperative dose but should be considered for patients on a strict sodium-restricted diet.

How Does Sugammadex Adroiq Interact with Other Drugs?

Drug interactions with sugammadex can be categorised into two distinct mechanisms. The first involves displacement interactions, where other medications with higher binding affinity for sugammadex can displace the neuromuscular blocking agent from the sugammadex complex, potentially leading to recurrence of neuromuscular blockade. The second involves complex-forming interactions, where sugammadex itself binds to other drugs, reducing their effectiveness. A third category involves in vitro pharmacodynamic effects on coagulation parameters that are generally not clinically significant.

Major Interactions

When certain medications are administered after Sugammadex Adroiq, they could theoretically cause rocuronium or vecuronium to be displaced from the sugammadex molecule. If this occurs, the neuromuscular blocking effect may return, requiring ventilatory support and possible re-dosing of sugammadex or the use of an alternative non-steroidal neuromuscular blocker. Patients should therefore be monitored for signs of recurrence of blockade for up to 15 minutes if another drug is administered parenterally within 7.5 hours of sugammadex. In the post-operative setting, toremifene (an anti-oestrogen used in breast cancer) and intravenous fusidic acid (an antibiotic) are the most relevant examples.

Minor and Pharmacodynamic Interactions

Sugammadex may bind to certain other drugs administered concurrently, thereby reducing their free plasma concentration and clinical effect. The most clinically relevant example is the interaction with hormonal contraceptives, particularly progestogens. Pharmacodynamic interactions with anticoagulants (heparins, vitamin K antagonists, direct oral anticoagulants) have been observed in vitro but are rarely clinically meaningful in routine postoperative thromboprophylaxis.

Effect on Hormonal Contraceptives

Sugammadex can reduce the effectiveness of hormonal contraceptives, including combined oral contraceptive pills, progestogen-only pills, vaginal rings, implants, and hormonal intrauterine devices. The interaction results from sugammadex binding to progestogen in the circulation, reducing its free plasma concentration. Pharmacokinetic modelling suggests the effect is equivalent to one missed oral contraceptive pill.

Re-Administration of Neuromuscular Blocking Agents

If neuromuscular blockade is required again after reversal with Sugammadex Adroiq, specific waiting times must be observed before re-administering rocuronium or vecuronium. These waiting times depend on the dose of sugammadex previously given and the intended dose of the neuromuscular blocking agent. If rapid re-paralysis is needed before the recommended waiting time has elapsed, a non-steroidal neuromuscular blocking agent such as cisatracurium should be used instead.

What Is the Correct Dosage of Sugammadex Adroiq?

Sugammadex Adroiq should only be administered by, or under the direct supervision of, an anaesthesiologist. The use of objective neuromuscular monitoring (preferably quantitative train-of-four) is strongly recommended to assess the depth of blockade and determine the appropriate timing and dose of reversal. All doses are calculated based on actual body weight, including in patients with obesity (BMI ≥ 40 kg/m²) and in paediatric patients.

Adults

Children (2 to 17 Years)

Sugammadex Adroiq is approved for routine reversal of rocuronium-induced blockade in paediatric patients aged 2 to 17 years. The weight-based dosing is the same as for adults:

• 2 mg/kg at reappearance of T2 (routine reversal of moderate blockade)
• 4 mg/kg at 1–2 PTC (routine reversal of deep blockade)

For paediatric patients, Sugammadex Adroiq 100 mg/ml may be diluted to 10 mg/ml with 0.9% sodium chloride to improve dosing accuracy, particularly in younger children where small volumes are critical.

Elderly Patients

Conditions associated with prolonged circulation time, including advanced age, may be associated with longer recovery times. While the dose recommendations are the same as for other adults, elderly patients may experience slightly slower reversal. No dose adjustment is required, but cardiovascular and respiratory monitoring should continue as for any patient emerging from anaesthesia.

Renal Impairment

Sugammadex is primarily excreted renally. Sugammadex Adroiq is not recommended for patients with severe renal impairment (creatinine clearance below 30 ml/min) or those requiring dialysis. For patients with mild or moderate renal impairment, the standard dose can be used; however, the waiting time before re-administering rocuronium (0.6 mg/kg) or vecuronium (0.1 mg/kg) should be extended to 24 hours. If sugammadex is inadvertently administered to a patient with severe renal impairment and removal is clinically necessary, haemodialysis with a high-flux filter can reduce plasma concentrations by up to 70% over 3–6 hours.

Patients with Obesity

For patients with obesity, including morbid obesity (BMI ≥ 40 kg/m²), the dose should be calculated using actual body weight rather than ideal or lean body weight. The same dosing recommendations as for other adults apply. Clinical studies in patients with morbid obesity have confirmed that this approach provides reliable and complete reversal.

Missed Dose

Because Sugammadex Adroiq is administered as a single intravenous bolus in the operating theatre or immediate post-anaesthesia area, there is no concept of a "missed dose" in the outpatient sense. The decision to administer and the exact timing are determined by the anaesthesiologist on the basis of intraoperative neuromuscular monitoring and clinical judgement. If reversal is believed to have been incomplete (for example, if signs of residual blockade appear in recovery), an additional dose may be given by the anaesthetic team in accordance with local protocols.

Overdose

In clinical studies, one case of accidental overdose at 40 mg/kg was reported without significant adverse effects. In a human tolerability study, doses up to 96 mg/kg were administered with no dose-related serious adverse effects. There is no specific antidote. Sugammadex can be removed by haemodialysis using a high-flux filter (up to 70% plasma concentration reduction after 3–6 hours), but not with a low-flux filter. In the event of a suspected overdose, supportive care and continued neuromuscular and cardiovascular monitoring are the mainstays of management.

What Are the Side Effects of Sugammadex Adroiq?

Like all medicines, Sugammadex Adroiq can cause side effects, although not everybody experiences them. Because Sugammadex Adroiq is administered alongside other anaesthetic agents and neuromuscular blocking agents in the surgical setting, establishing a clear causal relationship for many adverse events is challenging. The safety profile of sugammadex has been evaluated in more than 3,500 subjects in pooled Phase I–III studies and extensively characterised through post-marketing surveillance. As a generic bioequivalent, Sugammadex Adroiq is expected to share this safety profile.

Hypersensitivity: Detailed Information

In a dedicated randomised, double-blind study in healthy volunteers receiving up to three doses of sugammadex, the incidence of adjudicated hypersensitivity was 1.3% in the placebo group, 6.6% in the sugammadex 4 mg/kg group, and 9.5% in the sugammadex 16 mg/kg group. Verified anaphylaxis occurred in one subject at the 16 mg/kg dose (incidence 0.7%). In an earlier study of similar design, three verified cases of anaphylaxis were reported, all at 16 mg/kg (incidence 2.0%). There was no evidence of increased frequency or severity with repeated dosing. Post-marketing experience has identified hypersensitivity both to sugammadex alone and to the sugammadex-rocuronium complex. Reactions have occurred in patients with no prior exposure to sugammadex, so vigilance is required on every administration.

Special Populations

Patients with pulmonary disease: Bronchospasm has been reported as a possibly related adverse reaction, more frequently in patients with a history of pulmonary complications or reactive airway disease. Clinicians should be vigilant for this possibility and consider prophylactic bronchodilator therapy where appropriate.

Paediatric patients: In studies of children aged 2 to 17 years, the safety profile at doses up to 4 mg/kg was generally similar to that in adults, with no clinically meaningful differences in the frequency or nature of adverse reactions.

Patients with morbid obesity: Dedicated clinical studies have confirmed that the safety profile in patients with BMI ≥ 40 kg/m² is generally similar to that of the overall adult population when dosing is based on actual body weight.

ASA class 3–4 patients: In a study of patients with severe systemic disease, the adverse event profile was generally similar to the pooled adult data, although overall event rates were higher as expected in this higher-risk group.

Reporting of Side Effects

If you experience any side effects, discuss them with your surgical team, anaesthesiologist, or primary care provider. In many countries, patients and healthcare professionals can also report suspected adverse drug reactions directly to the national pharmacovigilance authority — for example the FDA MedWatch system in the United States, the MHRA Yellow Card Scheme in the United Kingdom, or the EMA EudraVigilance system in the European Union. Such reporting helps improve knowledge about the safety of Sugammadex Adroiq and other generic sugammadex products.

How Should Sugammadex Adroiq Be Stored?

Storage of Sugammadex Adroiq is handled by healthcare professionals in the hospital pharmacy or operating theatre environment. Patients generally do not store this medicine themselves. The following general storage guidelines apply and should be confirmed against the specific product packaging and the local prescribing information:

• Unopened vials: Store below 30°C. Do not freeze. Keep the vials in the outer carton to protect from light. Shelf life is as indicated on the label, typically 2–3 years from manufacture.
• After opening or dilution: Store at 2–8°C and use within 24 hours. Chemical and physical stability data indicate that sugammadex is stable for up to 48 hours at 2–25°C after dilution, but from a microbiological standpoint, the diluted product should be used immediately unless dilution was performed under controlled and validated aseptic conditions.
• Appearance: Sugammadex Adroiq is a clear, colourless to slightly yellow or brownish-yellow solution. Do not use if the solution appears discoloured beyond these limits or contains visible particulate matter.
• Do not use after the expiry date shown on the carton and vial label. The expiry date refers to the last day of that month.

Compatibility with Intravenous Fluids

Sugammadex Adroiq can be injected into an intravenous line concurrently running with: 0.9% sodium chloride, 5% glucose, 0.45% sodium chloride with 2.5% glucose, Ringer's lactate solution, or Ringer's solution. The intravenous line must be flushed thoroughly (e.g. with 0.9% sodium chloride) between the administration of Sugammadex Adroiq and other drugs to avoid physical or chemical incompatibility. Known physical incompatibilities exist with verapamil, ondansetron, and ranitidine, among others — these agents must not be mixed in the same line at the time of sugammadex administration.

Disposal

Any unused medicine should be disposed of in accordance with local requirements and hospital pharmaceutical waste procedures. Do not dispose of medicines via wastewater or household waste. These measures help to protect the environment and reduce the risk of inappropriate use.

What Does Sugammadex Adroiq Contain?

Active Ingredient

The active substance is sugammadex, supplied as sugammadex sodium. Each 1 ml of solution for injection contains sugammadex sodium equivalent to 100 mg of sugammadex. Sugammadex Adroiq is typically available in two vial sizes:

• 2 ml vial: 200 mg of sugammadex
• 5 ml vial: 500 mg of sugammadex

Inactive Ingredients (Excipients)

• Water for injections
• Hydrochloric acid 3.7% (for pH adjustment)
• Sodium hydroxide (for pH adjustment)

The formulation is preservative-free. Vials are intended for single use only; any unused portion should be discarded.

Packaging

Sugammadex Adroiq is supplied in packs containing 2 ml or 5 ml clear glass vials with rubber stoppers and aluminium seals. Pack sizes may vary by country; not all pack sizes may be marketed in all regions. For exact pack size, batch number, and manufacturer details applicable to a specific market, refer to the patient information leaflet supplied with the product or your hospital pharmacy.

Marketing Authorisation and Manufacturer

Sugammadex Adroiq is a generic medicinal product and is marketed under a separate marketing authorisation from the originator sugammadex. Full details of the marketing authorisation holder, manufacturer, and distribution in each country are provided on the product packaging and in the country-specific Summary of Product Characteristics (SmPC) or package insert.

References

1. European Medicines Agency (EMA). Sugammadex — Summary of Product Characteristics (generic sugammadex products). Last updated 2025. Available at: www.ema.europa.eu/en/medicines
2. U.S. Food and Drug Administration (FDA). Sugammadex Prescribing Information. Reference approval NDA 022225. Available at: www.accessdata.fda.gov
3. Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database of Systematic Reviews. 2017;(8):CD012763. doi:10.1002/14651858.CD012763
4. Carron M, Zarantonello F, Lazzarotto N, Tellaroli P, Ori C. Role of sugammadex in accelerating postoperative discharge: A meta-analysis. Journal of Clinical Anesthesia. 2017;39:38–44.
5. Puhringer FK, Rex C, Sielenkamper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008;109(2):188–197.
6. World Health Organization. WHO Model List of Essential Medicines — 23rd List (2023). Geneva: WHO; 2023. Available at: www.who.int
7. Fuchs-Buder T, Meistelman C, Raft J. Sugammadex: clinical development and practical use. Korean Journal of Anesthesiology. 2013;65(6):495–500.
8. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesthesia and Analgesia. 2007;104(3):575–581.
9. British National Formulary (BNF). Sugammadex monograph. London: Joint Formulary Committee; updated 2025. Available at: bnf.nice.org.uk
10. Herring WJ, Mukai Y, Wang A, et al. A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants. BMC Anesthesiology. 2021;21:259.

Editorial Team

Evidence standard: All medical claims in this article are supported by Level 1A evidence from systematic reviews, randomised controlled trials, and official regulatory documents (EMA SmPC, FDA prescribing information, BNF, WHO Essential Medicines List). This content is updated regularly to reflect the latest approved prescribing information for sugammadex-containing products.

Conflict of interest statement: iMedic receives no funding from pharmaceutical companies. All editorial content is independent and free from commercial influence. Generic and originator products are discussed neutrally on the basis of clinical evidence.